Itzel Viridiana Reyes-Pérez

Targeting MyD88 Downregulates Inflammatory Mediators and Pathogenic Processes in PBMC From DMARDs-Naïve Rheumatoid Arthritis Patients

I. V. Reyes-Pérez, P. Bhattaram, E. Oregon-Romero, 2021, Frontiers in Pharmacology.

Cytokines (IL-15, IL-21, and IFN-γ) in rheumatoid arthritis: association with positivity to autoantibodies (RF, anti-CCP, anti-MCV, and anti-PADI4) and clinical activity

J. Muñóz-Valle, I. V. Reyes-Pérez, P. E. Sánchez-Hernández, 2019, Clinical Rheumatology.

Targeting inflammasome-dependent mechanisms as an emerging pharmacological approach for osteoarthritis therapy

I. V. Reyes-Pérez, P. Bhattaram, Luis Alexis Hernández-Palma, 2022, iScience.

Comments on “Killer immunoglobulin‐like receptor repertoire analysis in a Caucasian Spanish cohort with inflammatory bowel disease”

J. Macías-Barragán, Moisés Enciso-Vargas, Omar Graciano-Machuca, 2020, Microbiology and immunology.

Myositis-Specific Antibodies and Myositis-Associated Antibodies in Patients With Idiopathic Inflammatory Myopathies From the PANLAR Myositis Study Group

M. Fritzler, L. Andrade-Ortega, I. V. Reyes-Pérez, 2020, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.